Tag Archives: AMGN

Best Biotech Stocks To Buy Right Now

Monday was a good start to the week for stocks, with major benchmarks climbing around half a percent on the day. Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the generally positive attitude among investors.

But there are still plenty of factors that are preventing stocks overall....More>>>

Top Biotech Stocks To Buy Right Now

Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Spectrum Pharmaceuticals Inc is a biotechnology company in the United States. It develops drugs to cure serious diseases such as chemotherapy-induced neutropenia in patients with breast cancer. Spectrum Pharmaceuticals Inc has a market cap of $1.81 billion; its shares were traded....More>>>

Top 5 Biotech Stocks To Invest In Right Now

Vical (NASDAQ:VICL) has been a horror show for investors. Failed trials, poor technology and a lack of awareness have left this small biotech company from San Diego all but forgotten. There are many reasons that a long-term investor would have no interest in this company even though it passes Benjamin Graham’s criteria as a net-net investment because it is trading below cash. I believe there....More>>>

Best Biotech Stocks To Buy For 2019

Eiger Biopharmaceuticals (NASDAQ:EIGR) had its price objective increased by research analysts at Piper Jaffray to $28.00 in a research report issued to clients and investors on Friday. The firm currently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray’s price objective points to a potential upside of 101.44% from the stock’s previous....More>>>

Hot Biotech Stocks To Watch Right Now

Biotech stocks are known for dramatic gains, and this year’s top performers are helping the industry live up to its reputation. Investors excited about the future of gene therapy have seen CRISPR Therapeutics AG (NASDAQ:CRSP) more than quadruple its shareholders’ money over the past year.

The gene-editing stock has put up a dazzling performance, but it pales in comparison to Endocyte....More>>>